Firalis S.A. is pleased to announce that 400 k€ were allocated by Bpifrance for our R&D program on precision medicine diagnostic tools for neurodegenerative diseases. Funding is supported by the French government through “France Relance” and “Territories of Industry” programs.
Alzheimer’s Disease (AD) is the most common type of age-related dementia, affecting around 50 million people worldwide and increasing constantly. Firalis S.A. develops a test to detect, identify and quantify innovative biomarkers for early diagnosis of AD, to improve patient care and support therapeutics by allowing a more efficient design for clinical research studies. Towards this purpose and thanks to this funding as well, Firalis is massively investing in laboratory equipment, extending its facilities to 4,000 sqm and recruiting experienced researchers; resulting in an overall much higher capacity to execute more research to develop new, innovative biomarker tools.
About FIRALIS S.A.
Firalis S.A. is a pioneering biotechnology company developing In-vitro diagnostic products through discovery, development and regulatory qualification of innovative biomarkers for precision medicine, to improve prognosis and therapeutic decisions within fields of cardiovascular (e.g. Heart Failure), neurodegenerative (AD & other Dementias) and inflammatory/autoimmune diseases and disorders. Firalis uses cutting-edge technology platforms, with an expert team of 60 people working in an exceptional environment, certified and accredited for the highest quality standards requested by the biopharmaceutical industry. Furthermore, Firalis has a solid partnership with a highly competent network of clinicians from 13 clinical centers of excellence in neurology and has been awarded with numerous research and entrepreneurship awards as well as significant research grants to conduct some of the largest clinical biomarker studies ever.
Press contact: email@example.com